Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to compare the efficacy of alemtuzumab with other MS disease modifying therapies (DMTs) in relapsing-remitting MS (RRMS).

Next Previous
X
Search
Trial Profile

Study to compare the efficacy of alemtuzumab with other MS disease modifying therapies (DMTs) in relapsing-remitting MS (RRMS).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Nov 2017 New trial record
    • 28 Oct 2017 Results assessing efficacy of alemtuzumab with other MS disease modifying therapies (DMTs) in relapsing-remitting MS (RRMS), were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top